Add genetics

to your health.

A timely genetic diagnosis
can improve and save lives.

Whether it’s because of a known genetic predisposition, the desire to start medical treatment early to prevent or delay a possible disease progression or simply to address a nagging uncertainty, there are many different personal reasons to look for a dependable genetic diagnosis. It’s about your quality of life. You deserve to feel reassured about the state of your health.

With the medical expertise of arcensus, you can find this reassurance in a manner that is precise, quick and which guarantees the highest levels of data protection. Gain certainty where it really matters – for you and for your whole family. In this vital process, we support you every step of the way.
Welcome to arcensus.

Michael Schlenk - CEO

“I have all these great genes, but they're recessive. That's the problem here.”


The complete 
Calvin and Hobbes

“Don’t be ashamed or proud of your genetics, for you have no contribution towards it.”


“The laws of genetics apply even if you refuse to learn them.”


“A four-letter alphabet called DNA.”


The Red Queen: Sex and the Evolution of Human Nature

“My genetics have been in my family for generations.”


The Stork ate my Brother...And other totally believable Stories

“You inherit your environment just as much as your genes."


The Human Script

How it works

We serve the health of our clients with specialist knowledge and passion.

The heart of arcensus is an interdisciplinary team of experienced medical professionals headquartered in Germany and operating globally. Our profound understanding of genetics helps you to receive the best service for improving the state of your health today and in the future. We provide safe, easy and affordable genetic testing worldwide for everyone. We are greatly committed to sustainable support. The diagnosis of genetic conditions and the development of appropriate pharmaceutical drugs are assisted and accelerated by the most up-to-date scientific methods.

Testing your entire genome is a once-in-a-lifetime procedure – only one blood sample is required to provide comprehensive answers to crucial medical questions, whatever they might be.
Direct-to-consumer (DTC) genetic tests, which can be obtained without a physician’s order, are often used recreationally by individuals interested in learning more about genetic variants associated with medical disorders or treatment.

Genetic diseases

You have clinical symptoms that may be caused by a genetic condition.

Medical data

You feel healthy and are simply looking to gain medically relevant data from your genetics.

Got questions?

Hit us up with any questions, concerns or
 other information.

Our products

My risk to develop cancer (mylifeCANCER)

Hereditary cancer predisposition syndromes are responsible for approximately 10% of all diagnosed cancer cases. The application of next generation sequencing (NGS) technology is widely used in clinical practice, for the identification of individuals with cancer predisposing gene variants.

My problem with fertility (mylifeFERTILITY)

Genetics play an important role in the evaluation of the infertile male and female. Infertility is a problem of the reproductive system defined by the failure to achieve a clinical pregnancy after more than 12 months of regular unprotected sexual intercourse. It affects 10-20% of couples worldwide and is attributed to males and females equally.

Get the drugs in the right dosage (mylifeDRUGS)

arcensus is offering a detailed, sophisticated and high-standard information regarding the influence of your genetic variations on the metabolism of different drugs; plenty of genes influencing drug metabolism in the human body.

Is there a risk for my child for a genetic disease (mylifeKIDS)

Genetic diseases may account for approximately 20% of infant mortality and hospitalizations. MyHealth-Kids helps to identify a couple's carrier status before pregnancy to enable informed decision. Carrier testing in a couple uncovers actionable results and is leading to more reproductive options for a family.

My risk to develop a heart disease (mylifeHEART)

Cardiovascular diseases are one of the most common causes of death in middle age and might start without any warning. Many different ailments are hidden behind this collective term. Often one disease causes the other, as for example in the case of cardiac arrhythmias, which can be triggered by heart valve disease.

YourHealth by arcensus.

Product line coming soon.

Ethical concerns of getting genetically tested?

When genetic testing is considered, there is always a balance between potential risks and benefits of acting on a test result. Although psychological preparation for diagnosis and treatment may be among the potential benefits of genetic testing, possible risks include loss of control over private information. These risks can have adverse effects on an individual or a family, such as changing life plans, particularly if there is misinformation, incomplete data, or misinterpretation. Genetic test results, like all medical records, are private data. To address this risk, arcensus stores genetic testing results in conjunction with personally identifiable data with advanced encryption technology and the strictest computer security measures.

Professional counseling is an important means to help patients understand these issues and ameliorate negative effects. Genetic counselling is an important part of the integrated solution arcensus offers. The interpretation of genetic risk involves deep expertise in clinical genetics; if wanted, supportive, psychological, educational, or reproductive counseling may also be used. We recommend that genetic tests ordered for diagnostic purposes should include counseling by a professional skilled in the interpretation of genetic test results. A detailed consent is always part of the process.
Direct-to-consumer (DTC) genetic tests, which can be obtained without a physician’s order, are often used recreationally by individuals interested in learning more about genetic variants associated with medical disorders or treatment.

Our team

Michael Schlenk,
CEO & Co-Founder

Michael has worked in the pharmaceutical and biotech industries for over 30 years, with more than 25 years as a CEO, business angel and investor in fast-growing biotech, pharma and IT companies. Michael has lived and worked all over the world and in more than 10 countries for companies including Sandoz/Novartis, Abbott and the NASDAQ-listed CENTOGENE N.V. He is highly experienced in building up and reorganising start-ups and technology companies. Today, he is head of the supervisory board of the IT company OXIXeSales AG in Freiburg as well as supervisory member of the MBA Programme at the University of Potsdam.
Michael founded arcensus together with Arndt Rolfs at the end of 2020.
Michael studied Business in Hamburg and completed an MBA Programme in the UK with the assistance of a BAT scholarship.


Christine Uekert,

Christine has worked for more than 20 years as a finance executive in fast-growing, innovative and international IT and life science businesses.
She has extensive experience in the areas of finance and controlling in internationally active, innovative and above all growing companies. Christine holds a degree in Business Economics and was most recently Chief Financial Officer at CENTOGENE AG, a global diagnostics company. There, she was responsible for developing the financial architecture and expansion strategy of the company and successfully supported growth corresponding to more than a tenfold increase in sales within five years. Furthermore, she has held several management positions in biotechnology and technology companies including curasan AG, ProBioGen AG, OD-OS GmbH, SPM Technologies GmbH and SAP Systems Integration AG.


Gabriela Elena Oprea, PhD,

Gabriela holds a PhD in Natural Science from University of Cologne, Germany and has been an active researcher in Human Genetics for almost 15 years. Her discovery and characterization of the first protective modifier of autosomal recessive spinal muscular atrophy [Science, 2008] gained her several awards. She is a highly motivated and experienced scientist in analysis, interpretation and utilization of genetic information within clinical context, efficiently turning big data into knowledge-based products. She acted as SVP Genetic Data Processing and Digital Products for more than seven years at CENTOGENE, where she contributed to the successful optimization and automation of genetic diagnostic and curation related processes. She had the opportunity to get in-depth exposure to big-data analysis and patterns discovery, along with successful proof-of-concept of AI application in variant classification, clinical statement generation and reporting. In 2020, Gabriela was appointed as General Director at Personal Genetics (Bucharest, Romania) where she remarkably implemented the next generation sequencing technology and methodology in house. Finding creative ideas how to improve and optimize „things”, drives her every day.


Doreen Niemann,
Chief of Staff

Doreen is a well-qualified and skilled manager with 15 years of vast experience in running overall daily operations of a company including e.g. staff management, strategic communication and marketing. In her current role, Doreen administers and structures the organization. Prior to joining arcensus, Doreen worked at CENTOGENE for several years in different positions, lastly as Executive Director CEO’s Office. Before that, she headed the Strategic Management at the Albrecht-Kossel-Institute for Neurodegeneration at the University of Rostock. Doreen studied Business Administration at the Hochschule für Technik, Wirtschaft und Kultur (HTWK) in Leipzig, Germany


Volha Skrahina, PhD,
Sr. Director Clinical Programs

Volha started her career with hereditary Sudden Death Syndrome research during her bachelor’s thesis at the Republican Theoretical and Practical Center – ‘Mother and Child’ in Minsk, Belarus. Afterwards, she investigated the translational regulation of the innate immune response in tuberculosis infection during her master’s thesis at the Max Plank Institute in Berlin, Germany. She has successfully completed PhD thesis on the host fungal micronutrient interaction at the Hans Knoell Institute in Jena, Germany in 2018. Till 2021 Volha has worked as a Director Clinical Studies in CENTOGENE. She with her team executed observational clinical studies worldwide to analyze the prevalence of rare diseases allowing patients to be diagnosed at the earliest possible moment. Additionally, she performed longitudinal observational clinical studies to validate or monitor biomarkers required for diagnosis and treatment personalization.